Decolonization Efficacy of Polyhexanide vs. Mupirocin

Launched by SWISS PARAPLEGIC RESEARCH, NOTTWIL · Oct 8, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new approach to help reduce the presence of a bacteria called Staphylococcus aureus, which can sometimes cause infections. The study compares two different treatments: one using a product called polyhexanide and the other using a standard treatment of mupirocin (an antibiotic) combined with chlorhexidine (a disinfectant). The goal is to see if the polyhexanide treatment can be as effective or better in helping patients who are scheduled for elective spine surgery and are already carrying this bacteria. The trial will involve 24 participants who will be divided into two groups to receive one of the treatments.

To be part of this trial, participants must be over 18 years old, scheduled for elective spine surgery, and have Staphylococcus aureus on their skin or in their nose. However, those who are having emergency surgery, are allergic to the treatments, or have certain other health issues won’t be eligible. During the trial, participants can expect to receive one of the treatments and will be monitored for how well it works and how they tolerate it. Importantly, this study is not yet recruiting participants, but it aims to help find better ways to prevent infections in surgical patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age over 18 years
• • Scheduled for elective spinal surgery
• • Colonized with Staphylococcus aureus
• • Informed consent provided
• Exclusion Criteria:
• • Emergency spine surgery
• • Methicillin-resistant Staphylococcus aureus (MRSA) or mupirocin-resistant S. aureus
• • Known allergies to products used in the trial
• • Pregnant or breastfeeding women
• • Recent antibiotic therapy (within 14 days)
• • Known non-compliance, substance abuse, or psychological disorders
• • Participation in another antimicrobial trial within the last 30 days